Pituitary tumours without distinct lineage differentiation express stem cell marker SOX2
Authors' conclusion
Our study is the first to biologically characterise pituitary tumours WDLD. We demonstrate that these tumours exhibit a higher expression of the stem cell marker SOX2 compared with other lineage-differentiated tumours, suggesting possible involvement of stem cells in their development.
Study context
- Population
- Surgically resected pituitary tumours, St Vincent's Hospital, Sydney, selected to cover a range of tumour types
- Participants
- 10 vs 42
- Exposure
- Tumours without distinct lineage differentiation (WDLD) vs tumours meeting WHO lineage criteria
- WDLDn = 10
- Lineage criterian = 42reference
- Outcome
- Expression of stem cell markers (SOX2, Nestin, CD133)
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
SOX2 positive on immunohistochemistry
WDLD
70
7 of 10
Lineage criteria
23.4%
10
P = 0.005
Observational data: associations, not effects.
Further findings
Events
| Outcome | WDLD | Lineage criteria | P value |
|---|---|---|---|
| CD133 positive on immunohistochemistry | 2 | 0 | P = 0.003 |
- CD133 positive on immunohistochemistry: 2/10 vs 0/41
Relative expression of stem cell markers (SOX2, CD133, Nestin) on RT-qPCR
- No significant difference between tumours with and WDLD
Original publication
Pituitary tumours without distinct lineage differentiation express stem cell marker SOX2. Pituitary. Published 14 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →